Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/24082

Title: Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).
Authors: Coles, A. J.
Boyko, A. N.
Cohen, J. A.
De Seze, J.
Fox, E. J.
Havrdova, E.
Hartung, H. -P.
Inshasi, J. S.
McCombe, P.
Selmaj, K. W.
Vermersch, P.
Van Wijmeersch, Bart
Margolin, D. H.
Thangavelu, K.
Rodriguez, C. E.
Montalban, X.
Issue Date: 2016
Citation: MULTIPLE SCLEROSIS JOURNAL, 22, p. 75-76 (Art N° 213)
Notes: [Coles, A. J.] Univ Cambridge, Sch Med, Cambridge, England. [Boyko, A. N.] Pirogov Russian Natl Res Univ, Moscow, Russia. [Boyko, A. N.] Usupov Hosp, Demyelinating Dis Ctr, Moscow, Russia. [Cohen, J. A.] Cleveland Clin, Cleveland, OH 44106 USA. [De Seze, J.] Univ Strasbourg, Strasbourg, France. [Fox, E. J.] Cent Texas Neurol Consultants, Round Rock, TX USA. [Havrdova, E.] Charles Univ Prague, Med Fac 1, Prague, Czech Republic. [Hartung, H. -P.] Heinrich Heine Univ, Dusseldorf, Germany. [Inshasi, J. S.] Rashid Hosp, Dubai, U Arab Emirates. [Inshasi, J. S.] Dubai Med Coll, Dubai, U Arab Emirates. [McCombe, P.] Univ Queensland, Brisbane, Qld, Australia. [Selmaj, K. W.] Med Univ Lodz, Lodz, Poland. [Vermersch, P.] Univ Lille Nord France, Lille, France. [Van Wijmeersch, B.] Univ Hasselt, Hasselt, Belgium. [Margolin, D. H.; Thangavelu, K.; Rodriguez, C. E.] Sanofi Genzyme, Cambridge, MA USA. [Montalban, X.] MS Ctr Catalonia, Barcelona, Spain.
URI: http://hdl.handle.net/1942/24082
ISI #: 000383267200122
ISSN: 1352-4585
Category: M
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
N/A447.95 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.